|
Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington (a suburb of Seattle), is the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Antibody-drug Conjugates are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity. The companys' flagship product Adcetris (Brentuximab vedotin) 〔(Brentuximab vedotin (SGN35) ), ADC Review/Journal of Antibody-drug Conjugates〕 is commercially available for two indications in 50 countries, including the U.S., Canada, Japan and members of the European Union. The approval of Brentuximab vedotin makes it the first in a new class of ADCs. To expand on the clinical opportunities of brentuximab vedotin, Seattle Genetics is conducting a broad clinical development program 〔(Brentuximab vedotin (ADCETRIS®) Clinical Trials ), ADC Review/Journal of Antibody-drug Conjugates〕 to evaluate its therapeutic potential in earlier lines of its approved indications as well as in a range of other lymphoma and non-lymphoma settings. The company is jointly developing brentuximab vedotin in collaboration with Takeda Pharmaceutical Company. Under the terms of the collaboration, Seattle Genetics has full commercialization rights to brentuximab vedotin in the United States and Canada. Takeda has exclusive rights to commercialize the product candidate in all other countries. In addition to brentuximab vedotin, Seattle Genetics' product pipeline includes SGN-CD19A, an Antibody-drug conjugate (ADC) targeting CD19, SGN-CD33A, an ADC targeting CD33, SGN-LIV1A, an ADC targeting LIV-1, SGN-CD70A, an ADC targeting CD70, as well as ASG-22ME and ASG-15ME, ADCs that we are co-developing with Agensys (an affiliate of Astellas), an early-stage privately held biotechnology company based in Los Angeles, focusing on the development of fully human monoclonal antibodies to treat solid tumor cancers in a variety of cancer targets. ==Collaboration Agreements== Seattle Genetics has collaboration agreements with Takeda Oncology Company (formerly Millennium) to develop and commercialize brentuximab vedotin. The company also has collaboration agreements for their ADC technology with a number of biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd. (formerly part of Abbott Laboratories), AbbVie; Bayer Pharmaceuticals Corporation, Celldex Therapeutics, Inc., Daiichi Sankyo Co., Ltd., Genentech, Inc., GlaxoSmithKline LLC, Pfizer, Inc. and PSMA Development Company LLC as well as ADC co-development agreements with Agensys, Inc., an affiliate of Astellas Pharma, Inc. and Oxford BioTherapeutics Ltd.〔(Seattle Genetics Corporate Profile ) Reuters〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Seattle Genetics」の詳細全文を読む スポンサード リンク
|